Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Accelerated approval for pertuzumab in the neoadjuvant setting: winds of change?

Esserman LJ, DeMichele A.

Clin Cancer Res. 2014 Jul 15;20(14):3632-6. doi: 10.1158/1078-0432.CCR-13-3131. Epub 2014 Apr 18.

2.
3.

Pertuzumab in the treatment of HER2+ breast cancer.

Jhaveri K, Esteva FJ.

J Natl Compr Canc Netw. 2014 Apr;12(4):591-8. Review.

PMID:
24717573
4.

Pertuzumab for the treatment of breast cancer.

Lynce F, Swain SM.

Cancer Invest. 2014 Oct;32(8):430-8. doi: 10.3109/07357907.2014.922570. Epub 2014 Jun 12. Review.

PMID:
24921704
5.

Role of Anti-HER-2 Therapies in the Neo-Adjuvant Setting: Is Complete Pathological Response a Solid Surrogate?

Valsecchi ME, Díaz-Cantón E.

Rev Recent Clin Trials. 2015;10(2):82-9. Review.

PMID:
26216436
6.

Neoadjuvant therapy as a platform for drug development and approval in breast cancer.

Bardia A, Baselga J.

Clin Cancer Res. 2013 Dec 1;19(23):6360-70. doi: 10.1158/1078-0432.CCR-13-0916. Review.

7.

First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer.

Amiri-Kordestani L, Wedam S, Zhang L, Tang S, Tilley A, Ibrahim A, Justice R, Pazdur R, Cortazar P.

Clin Cancer Res. 2014 Nov 1;20(21):5359-64. doi: 10.1158/1078-0432.CCR-14-1268. Epub 2014 Sep 9. Review.

8.

[Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].

Sabatier R, Gonçalves A.

Bull Cancer. 2014 Jul-Aug;101(7-8):765-71. doi: 10.1684/bdc.2014.1940. French.

PMID:
25091659
9.

Is the Preoperative Setting an Appropriate Platform for Drug Approval in Breast Cancer?

Kaklamani VG, Gradishar WJ.

J Natl Compr Canc Netw. 2015 Nov;13(11):1448-52. No abstract available.

PMID:
26553770
10.

Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer.

Dawood S, Sirohi B.

Future Oncol. 2015;11(6):923-31. doi: 10.2217/fon.15.7. Review.

PMID:
25760974
11.

Pertuzumab: development beyond breast cancer.

Barthélémy P, Leblanc J, Goldbarg V, Wendling F, Kurtz JE.

Anticancer Res. 2014 Apr;34(4):1483-91. Review.

PMID:
24692675
12.

Neoadjuvant pertuzumab: the exception that proves the rule?

Burstein HJ.

Oncology (Williston Park). 2014 Mar;28(3):197-9. No abstract available.

13.

Pertuzumab in breast cancer: a systematic review.

Zagouri F, Sergentanis TN, Chrysikos D, Zografos CG, Filipits M, Bartsch R, Dimopoulos MA, Psaltopoulou T.

Clin Breast Cancer. 2013 Oct;13(5):315-24. doi: 10.1016/j.clbc.2013.05.002. Epub 2013 Jun 27. Review.

PMID:
23810292
14.

Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer.

O'Sullivan CC, Swain SM.

Expert Opin Biol Ther. 2013 May;13(5):779-90. doi: 10.1517/14712598.2013.783007. Epub 2013 Mar 27. Review.

PMID:
23530718
15.

Neoadjuvant trials could speed up drug approvals.

Peres J.

J Natl Cancer Inst. 2014 Mar;106(3):dju072. doi: 10.1093/jnci/dju072. Epub 2014 Mar 7. No abstract available.

PMID:
24610911
16.

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.

Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, Moliterni A, Vazquez F, Byakhov MJ, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Magazzù D, Heinzmann D, Steinseifer J, Valagussa P, Baselga J.

Lancet Oncol. 2014 May;15(6):640-7. doi: 10.1016/S1470-2045(14)70080-4. Epub 2014 Mar 20.

PMID:
24657003
17.

Drug development: neoadjuvant opportunities in breast cancer.

Rastogi P, Geyer CE, Mamounas EP, DeMichele A.

Am Soc Clin Oncol Educ Book. 2013:73-9. doi: 10.1200/EdBook_AM.2013.33.73.

18.

The Role of Neoadjuvant Trials in Drug Development for Solid Tumors.

Funt SA, Chapman PB.

Clin Cancer Res. 2016 May 15;22(10):2323-8. doi: 10.1158/1078-0432.CCR-15-1961. Epub 2016 Feb 3. Review.

19.

[Pertuzumab and solid tumors: perspectives].

Barthélémy P, Leblanc J, Wendling F, Wissler MP, Bergerat JP.

Bull Cancer. 2014 Dec;101(12):1114-21. doi: 10.1684/bdc.2014.2026. French.

PMID:
25532690
20.

Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.

Attard CL, Pepper AN, Brown ST, Thompson MF, Thuresson PO, Yunger S, Dent S, Paterson AH, Wells GA.

J Med Econ. 2015 Mar;18(3):173-88. doi: 10.3111/13696998.2014.979938. Epub 2014 Nov 10.

PMID:
25347449

Supplemental Content

Support Center